Last updated: July 17, 2026

Application No. 18/799,503

THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER

Non-Final OA

Filed

Aug 09, 2024

Priority

Sep 19, 2018 — provisional 62/733,573 +2 more

Examiner

GUSTILO, ESTELLA M

Art Unit

1646

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Genentech Inc.

OA Round

1 (Non-Final)

This examiner grants 53% of cases after interview

— +34.5% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 60 resolved cases, 2023–2026

Examiner Intelligence

GUSTILO, ESTELLA M View full profile →

Grants 53% of resolved cases

Career Allowance Rate

32 granted / 60 resolved

-6.7% vs TC avg

Strong +34% interview lift

Without

With

+34.5%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

32 currently pending

Career history

100

Total Applications

across all art units

Statute-Specific Performance

§101

0.5%

-39.5% vs TC avg

§103

48.4%

+8.4% vs TC avg

§102

12.7%

-27.3% vs TC avg

§112

9.4%

-30.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 60 resolved cases

Prosecution Timeline

Aug 09, 2024

Application Filed

May 05, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/771,367

Patent 12662543

ANTI-CD40 BINDING MOLECULES AND BI-SPECIFIC ANTIBODIES COMPRISING SUCH

4y 2m to grant Granted Jun 23, 2026

17/296,184

Patent 12655227

MODIFIED FC REGION

5y 0m to grant Granted Jun 16, 2026

18/152,595

Patent 12606605

ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE

3y 3m to grant Granted Apr 21, 2026

18/999,104

Patent 12595306

TREM2 STABILIZING ANTIBODIES

1y 3m to grant Granted Apr 07, 2026

18/897,951

Patent 12583925

BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGF

1y 5m to grant Granted Mar 24, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

53%

Grant Probability

88%

With Interview (+34.5%)

3y 5m (~1y 6m remaining)

Median Time to Grant

Low

PTA Risk

Based on 60 resolved cases by this examiner. Grant probability derived from career allowance rate.